Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.3389/fphar.2017.00825 https://repositorio.unifesp.br/handle/11600/58174 |
Resumo: | The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting H3R/H4R ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl) methyl] piperazine (LINS01 series) molecules were synthesized and evaluated as H3R and H4R ligands. Our data show that the N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pK(i) 6.40), while the chlorinated compound LINS01007 has moderate affinity for H4R (pK(i) 6.06). In addition, BRET assays to assess the functional activity of G(i)1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory. |
id |
UFSP_9c0f05d8b33d301c604f50148ab68e3a |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/58174 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory PotentialH3R antagonistsH4R antagonistshistamine receptorsdihydrobenzofuranSARanti-inflammatory activityasthmaThe histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting H3R/H4R ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl) methyl] piperazine (LINS01 series) molecules were synthesized and evaluated as H3R and H4R ligands. Our data show that the N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pK(i) 6.40), while the chlorinated compound LINS01007 has moderate affinity for H4R (pK(i) 6.06). In addition, BRET assays to assess the functional activity of G(i)1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory.Univ Fed Sao Paulo, Dept Ciencias Farmaceut, Diadema, BrazilUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim & Imunol, Ribeirao Preto, BrazilUniv Montreal, Inst Res Immunol & Canc, Dept Biochem & Mol Med, Montreal, PQ, CanadaUniv Fed Sao Paulo, Dept Ciencias Farmaceut, Diadema, BrazilWeb of ScienceFAPESPCNPqCAPESCanadian Institute for Health ResearchFAPESP: 2013/20479-9FAPESP: 2016/25028-3FAPESP: 2017/02042-3FAPESP: 2012/20148-0FAPESP: 2016/23139-2CNPq: 455411/2014-0Frontiers Media Sa2020-09-01T13:21:17Z2020-09-01T13:21:17Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion-application/pdfhttp://dx.doi.org/10.3389/fphar.2017.00825Frontiers In Pharmacology. Lausanne, v. 8, p. -, 2017.10.3389/fphar.2017.00825WOS000415041800005.pdf1663-9812https://repositorio.unifesp.br/handle/11600/58174WOS:000415041800005engFrontiers In PharmacologyLausanneinfo:eu-repo/semantics/openAccessCorrea, Michelle F. [UNIFESP]Barbosa, Alefe J. R. [UNIFESP]Teixeira, Larissa B.Duarte, Diego A.Simoes, Sarah C.Parreiras-e-Silva, Lucas T.Balbino, Aleksandro M. [UNIFESP]Landgraf, Richardt G. [UNIFESP]Bouvier, MichelCosta-Neto, Claudio M.Fernandes, Joao P. S. [UNIFESP]reponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-01T22:16:04Zoai:repositorio.unifesp.br/:11600/58174Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-01T22:16:04Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential |
title |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential |
spellingShingle |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential Correa, Michelle F. [UNIFESP] H3R antagonists H4R antagonists histamine receptors dihydrobenzofuran SAR anti-inflammatory activity asthma |
title_short |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential |
title_full |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential |
title_fullStr |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential |
title_full_unstemmed |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential |
title_sort |
Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H-3 and H-4 Receptors with Anti-inflammatory Potential |
author |
Correa, Michelle F. [UNIFESP] |
author_facet |
Correa, Michelle F. [UNIFESP] Barbosa, Alefe J. R. [UNIFESP] Teixeira, Larissa B. Duarte, Diego A. Simoes, Sarah C. Parreiras-e-Silva, Lucas T. Balbino, Aleksandro M. [UNIFESP] Landgraf, Richardt G. [UNIFESP] Bouvier, Michel Costa-Neto, Claudio M. Fernandes, Joao P. S. [UNIFESP] |
author_role |
author |
author2 |
Barbosa, Alefe J. R. [UNIFESP] Teixeira, Larissa B. Duarte, Diego A. Simoes, Sarah C. Parreiras-e-Silva, Lucas T. Balbino, Aleksandro M. [UNIFESP] Landgraf, Richardt G. [UNIFESP] Bouvier, Michel Costa-Neto, Claudio M. Fernandes, Joao P. S. [UNIFESP] |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Correa, Michelle F. [UNIFESP] Barbosa, Alefe J. R. [UNIFESP] Teixeira, Larissa B. Duarte, Diego A. Simoes, Sarah C. Parreiras-e-Silva, Lucas T. Balbino, Aleksandro M. [UNIFESP] Landgraf, Richardt G. [UNIFESP] Bouvier, Michel Costa-Neto, Claudio M. Fernandes, Joao P. S. [UNIFESP] |
dc.subject.por.fl_str_mv |
H3R antagonists H4R antagonists histamine receptors dihydrobenzofuran SAR anti-inflammatory activity asthma |
topic |
H3R antagonists H4R antagonists histamine receptors dihydrobenzofuran SAR anti-inflammatory activity asthma |
description |
The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting H3R/H4R ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl) methyl] piperazine (LINS01 series) molecules were synthesized and evaluated as H3R and H4R ligands. Our data show that the N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pK(i) 6.40), while the chlorinated compound LINS01007 has moderate affinity for H4R (pK(i) 6.06). In addition, BRET assays to assess the functional activity of G(i)1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 2020-09-01T13:21:17Z 2020-09-01T13:21:17Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.3389/fphar.2017.00825 Frontiers In Pharmacology. Lausanne, v. 8, p. -, 2017. 10.3389/fphar.2017.00825 WOS000415041800005.pdf 1663-9812 https://repositorio.unifesp.br/handle/11600/58174 WOS:000415041800005 |
url |
http://dx.doi.org/10.3389/fphar.2017.00825 https://repositorio.unifesp.br/handle/11600/58174 |
identifier_str_mv |
Frontiers In Pharmacology. Lausanne, v. 8, p. -, 2017. 10.3389/fphar.2017.00825 WOS000415041800005.pdf 1663-9812 WOS:000415041800005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Frontiers In Pharmacology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
- application/pdf |
dc.coverage.none.fl_str_mv |
Lausanne |
dc.publisher.none.fl_str_mv |
Frontiers Media Sa |
publisher.none.fl_str_mv |
Frontiers Media Sa |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268406359130112 |